Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 8/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.55 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.55 |
| ▸ | F9 | P00740 | 5/20 | 0.50 |
| ▸ | F10 | P00742 | 3/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 2/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1867721 | 0.88 | CLK1 (0.68) | CLK1DYRK1ADYRK1BBCL2L1CLK2 | |
| SCHEMBL3498352 | 0.85 | MCL1 (0.50) | CLK1DYRK1ADYRK1BF9F10 | |
| SCHEMBL3497047 | 0.83 | BCL2L1 (0.53) | CLK1DYRK1ADYRK1BF9F10 | |
| SCHEMBL121331 | 0.83 | F9 (0.67) | CLK1DYRK1ADYRK1BF9F10 | |
| SCHEMBL22777736 | 0.83 | F9 (0.67) | CLK1DYRK1ADYRK1BF9F10 | |
| SCHEMBL3498109 | 0.82 | F9 (0.50) | CLK1F9F10BCL2L1NR1H4 | |
| SCHEMBL3498640 | 0.82 | MAPT (0.52) | CLK1DYRK1ADYRK1BF9F10 | |
| SCHEMBL3498127 | 0.82 | CLK1 (0.60) | CLK1DYRK1ADYRK1BHDAC6HDAC1 | |
| SCHEMBL4601842 | 0.82 | F9 (0.56) | CLK1DYRK1ADYRK1BF9F10 | |
| SCHEMBL3498018 | 0.80 | BCL2L1 (0.53) | CLK1DYRK1ADYRK1BF9F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | CLK1 3974/4885DYRK1A 3028/4885DYRK1B 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.